In a corporate presentation, Apellis Pharmaceuticals disclosed that based on preliminary financial information, it expects to report that it recorded approximately $65M in net product revenue from sales of Empaveli in the United States for the year ended December 31, 2022.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on APLS:
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sell these stocks now, proven algorithm says
- Citi would buy Apellis on dip after talking to management about CMO change
- Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
- Apellis appoints Baumal as Chief Medical Officer
